AKTX — Akari Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $7.84m
- $4.00m
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 17 | 18 | 17.2 | 23.1 | 16.8 |
Operating Profit | -17 | -18 | -17.2 | -23.1 | -16.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -16.8 | -17.1 | -17.4 | -17.7 | -10 |
Net Income After Taxes | -16.8 | -17.1 | -17.4 | -17.7 | -10 |
Net Income Before Extraordinary Items | |||||
Net Income | -16.8 | -17.1 | -17.4 | -17.7 | -10 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -16.8 | -17.1 | -17.4 | -17.7 | -10 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.009 | -0.005 | -0.004 | -0.003 | -0.001 |